Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Collplant Biotechnologies Ltd

Current price
5.23 USD +0.0035 USD (+0.07%)
Last closed 5.35 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 61 271 944 USD
Yield for 12 month -29.23 %
21.11.2021 - 28.11.2021

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel. Address: Weizmann Science Park, Rehovot, Israel, 7670104


WallStreet Target Price

16.92 USD

P/E ratio

Dividend Yield

Current Year

+299 000 USD

Last Year

+15 641 000 USD

Current Quarter

+43 000 USD

Last Quarter

+10 184 000 USD

Current Year

-101 000 USD

Last Year

+13 636 000 USD

Current Quarter

-235 000 USD

Last Quarter

+9 569 000 USD

Key Figures CLGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -6 008 000 USD
Operating Margin TTM -10702.33 %
PE Ratio
Return On Assets TTM -11.39 %
PEG Ratio
Return On Equity TTM -19.74 %
Wall Street Target Price 16.92 USD
Revenue TTM 10 718 000 USD
Book Value 2.83 USD
Revenue Per Share TTM 0.95 USD
Dividend Share
Quarterly Revenue Growth YOY -60.6 %
Dividend Yield
Gross Profit TTM 13 636 000 USD
Earnings Share -0.59 USD
Diluted Eps TTM -0.59 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -62.8 %

Dividend Analytics CLGN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CLGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 2:3
Payout Ratio
Last Split Date 21.11.2016
Dividend Date 21.11.2016

Stock Valuation CLGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 4.9237
Enterprise Value Revenue 3.3017
Price Sales TTM 5.7167
Enterprise Value EBITDA -5.8901
Price Book MRQ 1.8912

Financials CLGN

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CLGN

For 52 weeks

4.7 USD 13.97 USD
50 Day MA 5.51 USD
Shares Short Prior Month 21 132
200 Day MA 6.99 USD
Short Ratio 1.41
Shares Short 17 788
Short Percent 0.21 %